Measuring access to medicines: a review of quantitative methods used in household surveys by Paniz, Vera Maria V et al.
Paniz et al. BMC Health Services Research 2010, 10:146
http://www.biomedcentral.com/1472-6963/10/146
Open Access RESEARCH ARTICLE
© 2010 Paniz et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Research article Measuring access to medicines: a review of 
quantitative methods used in household surveys
Vera Maria V Paniz*1,2, Anaclaudia G Fassa1, Maria de Fátima S Maia1, Marlos R Domingues1,3 and Andréa D Bertoldi1,2
Abstract
Background: Medicine access is an important goal of medicine policy; however the evaluation of medicine access is a 
subject under conceptual and methodological development. The aim of this study was to describe quantitative 
methodologies to measure medicine access on household level, access expressed as paid or unpaid medicine 
acquisition.
Methods: Searches were carried out in electronic databases and health institutional sites; within references from 
retrieved papers and by contacting authors.
Results: Nine papers were located. The methodologies of the studies presented differences in the recall period, 
recruitment of subjects and medicine access characterization.
Conclusions: The standardization of medicine access indicators and the definition of appropriate recall periods are 
required to evaluate different medicines and access dimensions, improving studies comparison. Besides, specific 
keywords must be established to allow future literature reviews about this topic.
Background
Universal medicine access is a major goal of the World
Health Organization (WHO) and of most countries with
respect to medicine policy[1]. This goal is included in the
objectives of the Millennium Development [2,3]. The
WHO defines medicines access as the equitable availabil-
ity and affordability of essential medicines during the
process of medicine acquisition [4]
The global situation of access to essential medicines is
still considered critical. Although the access to health
care is a fundamental human right and includes essential
medicine access, the World Health Organization (WHO)
estimates that nearly two billion people (1/3 of world
population) are not receiving regularly all medicines they
need. In developing countries the budget for medicines
corresponds to 24-66% of national health expenses, sup-
porting the monitoring of access to medicines in these
countries [3].
Nearly ten years ago the WHO developed a set of indi-
cators to evaluate drug policies[5]. Recently, the WHO
and the Management Science for Health (MSH) estab-
lished indicators and methods to evaluate pharmaceutical
assistance on three levels [5-8]. The level I evaluates
structure and process; level II evaluates results and; level
III evaluates each country's specific aspects. Within the
level II, methods to assess household-level medicines use
and access has already been tested in some countries,
including Brazil [1].
Household surveys are crucial to provide information
on how drug policies affect the individual's well being, as
this kind of study allows to evaluate access from the per-
spective of the individual, regardless of his/her use of
health services. This is especially relevant when evaluat-
ing medicine access to drugs prescribed for chronic con-
ditions, as these drugs may not be linked to a recent visit
to the doctor. However, household surveys are expensive
and logistically complex. The methodology suggested by
WHO and MSH evaluates if and how people are obtain-
ing their medicines, including how they use them, how
much is paid and what is the burden of this payment on
the overall family income [6].
Nonetheless, up to now there is no operational defini-
tion of medicine access, not even a model to monitor
medicine access in a country or to make comparisons
across countries [9]. Therefore, this review describes
quantitative methodologies to measure medicine access
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and explains how access is characterized. The advantages
and disadvantages of different methodologies are
described. The goal of the paper is to contribute to the
standardization of methodologies, increasing studies
comparability.
Methods
A literature review was performed in electronic data-
bases, health institutions websites, references of papers
retrieved and contact with authors. Electronic databases
were: PubMed, Lilacs, Embase, Web of Science and the
Scientific Electronic Library Online (SCIELO). The insti-
tutional websites were: the World Health Organization
http://www.who.int; Brazilian National School of Public
Health http://www.ensp.fiocruz.br, Brazilian Health
Ministry http://www.saude.gov.br, Pan American Health
Organization http://www.paho.org and the Management
Sciences for Health http://www.msh.org/seam.
With respect to the search, no limits were used and
keywords appearing on any field of the paper were
accepted. This strategy was chosen because recent papers
are more likely to be traced by title and/or abstract words,
for example, ahead of print papers.
The search was carried out using the following key-
words:  drug utilization; drug access; drug use habits;
essential drugs; drug prescription; drugs expenditures;
drug delivery systems; drug evaluation; self-medication;
pharmacoepidemiology; pharmaceutical preparations;
medication; medicine. As the words 'medicine' and 'drugs'
are highly cited in medical literature, many times as ille-
gal drugs, during search these words were combined with
other terms to make results more precise. The chosen
terms were: primary care; patient care; health care; pri-
mary health care; family health program; aging health;
health services; health services accessibility; hypertension;
diabetes mellitus; compliance; prescription; knowledge,
attitudes, practice; risk factors; aged; elderly.
Quantitative studies that measured medicine access on
household level as the main or secondary outcome and
were published until July 2008 were included in the analy-
sis. The access was defined as obtaining the medicine for
free or by payment [10]. Thus, studies about accessibility
(geographical access), adequacy (appropriateness of med-
icine prescribing) and medicine acceptability by the
patient were not included in the review.
The following exclusion criteria were employed: review
papers; qualitative design studies (once the methodology
do measure access is specific and not comparable to
quantitative studies); studies with data collection that
were not household-based interviews (this means that
demand studies or studies made in a health facilities were
excluded and the subjects in the study are not necessarily
users of health services); studies that, although home-
based, only measured affordability (health expenses), and
did not fulfill medicine access criterion for this review;
specific papers about medicine access for treatments
such as STD/AIDS (since each country has its own legis-
lation for distribution of these drugs), tuberculosis, Han-
sen's disease and endemic diseases control (malaria,
leishmaniasis, schistosomiasis, etc); studies about access
to high cost medicines prescribed for complex health
problems; studies with people covered by health insur-
ance plans (Medicare, Remediar), as they differ from
country to country depending on the medicine supply
methods; and studies on specific ethnic groups.
A box is presented at the end of the text showing infor-
mation retrieved from the selected papers. These data
were summarized to identify disadvantages and advan-
tages of employed methodologies (Figure 1).
Results
Using mainly the keyword medicine use [words]/drug
utilization [any field], more than 9000 titles and/or
abstracts were retrieved until July, 2008. After reading
titles/abstracts, nearly 8750 papers were excluded
because data collection was not home based. The papers
were mostly about demand, medicine availability, in the
public/private sector, medicine pricing/expenditure in
the public/private sector, medicine prescription studies,
health insurance coverage (based on secondary data), co-
payments impact or qualitative studies. From the remain-
ing papers, around 180 were excluded because did not
evaluate access or were review papers. In about 70 papers
we could not identify by the abstract if the approach was
the desired (home-based data collection about access),
and in those cases full texts were read and even if medi-
cine access was not the main outcome the study could be
included.
The references of selected studies were checked to find
other articles that could be included in the review.
Besides, author searches were carried out using relevant
names in the field. When more than one study was origi-
nated from the same data collection, only one study was
included in the review.
After manual search, impaired by the lack of specific
keywords to evaluate medicine access, nine studies were
included in this review [1,11-18].
I n  A d d i t i o n a l  f i l e  1  i t  c a n  b e  o b s e r v e d  t h a t  a m o n g
selected studies, six were conducted in South America
[1,11-15], two in North America [16,17] and one in Asia
[18], most were published after 2004. All studies were
cross-sectional [1,11-18], nearly half of the studies were
national [1,12,16,17] two were regional [15,18] and three
were municipal [11,13,14] and in only one study data col-
lection took place before the year 2000 [14].Paniz et al. BMC Health Services Research 2010, 10:146
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Medicine access was the main outcome of six out of
nine presented studies [1,11,15-18]. For the remainder
[12-14], evaluation of access was done by adherence stud-
ies [13] and medicines use [12,14]. With regard to key-
words, "drug utilization" was the most used (six studies)
[11,12,14-17] while only two studies included "access"
[11,17], although the term was not referring to medicines,
but to health services accessibility (Additional file 1).
Nearly half of the studies assessed the outcome by
instruments developed by the researchers [11,15,16,18].
Two studies utilized the methodology suggested by WHO
[1,12], and only aimed at evaluating medicine access [1],
the other was designed to evaluate health services perfor-
mance [12] (Additional file 1).
Additional file 2 presents population and assessed med-
icines, as well as the access definition used on each study.
As for the sample, six were population-based studies
[1,12-14,16,17], two studied the population covered by
Primary Care Unit [11,15] and one investigated local
health services users [18]. All studies evaluated medicine
access including the elderly [1,11-18], one third of studies
included all age groups [1,11,14] and three studied people
who were 18 or older [12,17,18]. The smallest sample size
was 248 people (all ages) [14], but most studies [1,11-
13,15-17] counted on sample sizes larger than 2000 peo-
ple.
The criterion employed to include subjects in the spe-
cific medicine access evaluation was not similar between
studies. Some studies recruited individuals based on the
need for the prescribed medicine [13,15,17], one study
was specific to three chronic conditions [15] and another
included subjects facing cost pressures [17]. Four studies
linked evaluation of the access to medicines prescribed in
the last visit to the doctor [1,12,14,18]; one study
excluded chronic conditions consultations [1]. From the
remaining two studies, one did not restrict sampling to
evaluate access, relying on respondent's report of medi-
cine need [11] and in another study, respondents who
reported that they used prescription medication for at
least one of the five chronic illnesses were asked about
access [16] (Additional file 2)
Figure 1 Information obtained from the selected studies.
1 - Place of study/ Year of publication 
2 - Design 
3 - Study level / Period / Year of data collection 
4 - Main goal of the study 
5 - Keywords: in addition to the initial keywords, the terms mentioned in the retrieved 
studies were also used. For papers without keywords (3 papers) keywords used were the 
same of the original search 
6 - Instrument: developed by the authors or by international organizations 
7 - Studied sample (not necessarily the whole sample of the study) 
8 – Recruitment strategies to evaluate access (beyond the inclusion criteria to participate 
in the study, one or more filter questions to evaluate medicine access are placed to 
restrict the population that will be analyzed for this particular topic, distinguishing it 
from the study sample) 
9 - Evaluated medicine: all, for acute problems, for chronic conditions 
10 - Access definition / Recall period 
11 - Question used to measure access 
12 - Administration of the instrument: face-to-face interviews, telephone, internet 
13 - Dropout and Response rates 
14 – Respondent: medicine user, user and parents, user and proxy or user and caregiver 
15 - Asking for the prescription, packet or leaflet 
16 - Data collection of the medicine name (if the study collected information about the 
obtained medicines without specifying the name, or if investigated the name of the 
medicines) Paniz et al. BMC Health Services Research 2010, 10:146
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In terms of assessed medicines, six studies investigated
all medicines types [11-14,17,18], one evaluated only
medicines prescribed to acute health problems [1] and
two other studies included only medicines used to treat
chronic conditions [15,16] (Additional file 2).
With respect to the definition of access, the studies pre-
sented distinct approaches and distinct recall periods,
from 15 days to 12 months. Two studies defined access as
obtaining medicines that were prescribed in the last visit
to the doctor during the 15 [1] or 30 [14] days prior to the
interview, while two other referred only to the last visit
with no mention of recall period [12,18]. One study
defined lack of medicine access when the person needed
but did not use the medicine in the last 15 days, regard-
less of medical prescription [11]. In two studies, access
was defined as obtaining medicines indicated by a doctor,
during a 30-day period [15] or 12-month period [17], and
only the latter discussed acquisition considering afford-
ability. However, in two studies [13,16], access was
defined using a very different criterion. One defined
access as adherence [13], that is, individuals that did not
interrupt medicine use in the last 12 months, regardless
of indication. In the other study [16], underuse was the
definition to measure access in a 30-day or 12-month
period for medicines prescribed to treat chronic condi-
tions (Additional file 2).
Additional file 3 describes the questions used to evalu-
ate medicine access and logistical aspects related to
administering the instruments of the studies included in
the review. Only one study did not present the question
used to evaluate medicines access [14]. Three studies
included the terminology "fail to use/take the medicine"
in the question [11,13,15], while four studies used the
terms "obtaining of the medicines prescribed/needed"
[1,12,17,18]. In two studies the access question referred to
affordability [16,17] and in two other studies the termi-
nology "took less medication than prescribed" was
employed [13,16].
From all studies, only one relied on internet informa-
tion (self-administered questionnaire) [16], eight studies
collected data by face-to-face interviews [1,11-15,17,18]
and one was by phone interview [17]. Three studies pre-
sented response rate below 85% [13,16,17]. Some papers
do not present clearly who was providing information
during interview/data collection [12,16-18] among the
studies that state who was the respondent, information
was provided by the user [1,11,13,15], by parents (studies
with children) [11] and by proxy or caregiver when
elderly subjects were studied [1,13]. Only one study used
information from the family head [14]. Asking for the
p a c k e t  o f  t h e  m ed i ci n e  was  a  s t r a t e gy  o f  m o s t  s t u d i e s
[1,11-13,15] that collected data face-to-face and in two
studies the methodology is not entirely described [14,18].
Only three studies adopted the strategy of asking for the
medicine prescriptions [11,12,15]. Besides evaluating
medicine access, five studies [1,11-13,15] also collected
the name of prescribed medicines, presented or reported
by the user, while the rest of studies did not present such
information [14,16-18] (Additional file 3).
Discussion
The acknowledgment of methodologies available to eval-
uate medicine access on household level is the first step
to establish strategies that will increase the understand-
ing of individual barriers to medicine access. However,
when summarizing methodologies, the first obstacle is
the search itself that demanded different strategies and
intense manual work. The literature about medicine
access on household level is sparse. Besides, the available
studies relied on distinct methodologies, impairing com-
parison. The following is a discussion of obstacles to the
review, and adjustments to methodological approaches
that could allow future comparisons. Although our inten-
tion was not to evaluate or to suggest new sampling
methods to measure medicine access, adequate sampling
techniques and high response rates are fundamental
methodological aspects to assure precision and validity in
any quantitative study.
Obstacles to the review
Keywords
The terms "medicine access" are not recognized as key-
words, making the search about this topic even more
complicated. The search for studies about medicine
access on household level results in many health services
and/or medicine access/use studies. However, chronic
users (chronic diseases medicines) or regular users (oral
contraceptives) may have medical indications to use
drugs without recent or regular visits to a doctor. Besides,
some medicines sold over the counter (antithermic medi-
cines) are not evaluated by this approach. Therefore, a
specific keyword to describe medicine access is needed,
to detect studies about this theme avoiding manual
searches.
Main goal of the study
The study of medicine access as a secondary goal [12-14]
may result in lower level of detail about this aspect and in
greatest difficulties in the bibliographic search. Usually,
medicine access is included in studies aiming to evaluate
medicines use. Many abstracts do not state clearly if the
study evaluated medicine access. Place and means of
acquisition (paid out-of-pocket/free of charge) are more
often mentioned. Thus, whenever utilization or service
indicators are mentioned, a complete reading of the paper
to check if medicine access was brought up is needed,
demanding exhaustive manual work.Paniz et al. BMC Health Services Research 2010, 10:146
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Access definition
One of the biggest obstacles to gather studies about this
topic is the diversity of indicators and dimensions used in
different definitions of the outcome, with no agreement
between studies. Even though during selection of the
studies for this review, a single definition was adopted -
"obtaining the needed medicine" [10], an attempt to
exclude studies that evaluated different access dimen-
sions such as availability, geographic accessibility and
a c c o m m o d a t i o n  [ 9 ] ,  w e  o b s e r v e d  t h a t  s u c h  d e f i n i t i o n
may include not only the medicine acquisition but also
the cost-related underuse [16], to evaluate if the individ-
ual cut back on treatment due to financial restrictions.
Medicine obtaining is represented by the affirmative that
the individual did not restrict medication or obtained all
prescribed medicines. On the other hand, underuse
seems to be another access definition, indicating that the
individual cut back on treatment or took less medicine
than prescribed. However, this approach (underuse) must
be taken cautiously as it could be understood simply as
not using medicine for any other reason and not lack of
access, if it is not clearly stated that the underuse is due to
cost.
Medicine adherence was the definition of access used
in one study [13], considering that if the individual took
less or did not take the prescribed medicine at all, there
was no adherence. However, if the reason for not taking
the medicine was the lack of affordability, the non-adher-
ence was actually lack of access to the medicine. Thus,
t h e  t e r m i n o l o gy  u s e d  i n  s u c h  s t u d i e s,  l i k e  u s e ,  a c c e s s,
adherence and rational use, must be clearly defined.
Place of the study/Year of publication
This review did not include studies about medicine
access for treatment of STD/AIDS and those designed to
evaluate only people covered by health insurances - most
studies carried out in the US. We also restricted the
search to home-based data collections. This strategy may
explain the high number of South American publications
retrieved.
Three studies carried out in Brazil belonged to the
World Health Survey, a multicenter (71 countries); to the
SABE project (Health Well-being and Aging), a study that
took place in six Latin American countries and The
Caribbean; and to the National Pharmaceutical Evalua-
tion, using the methodology suggested by the World
Health Organization for all countries[1,12,13]. We could
not find publications from the other countries about
medicine access referring to this project. However, this is
not a limitation of the review, because, as all studies had
to use the same methodology, only one study would be
included.
The increase in publications after 2004 may indicate
the concern of researchers with the monitoring of medi-
cines national policies, attempting to reach the goals of
WHO for the period 2004/2007 in response to the chal-
lenges in essential medicine access [3].
Methodological aspects of access evaluation
Study Level
Studies on national, state, regional or city level result in
different conclusions about medicine access. Distinct lev-
els may evaluate either national drug policies assistance
or specific national, regional or local programs [19].
Broader studies provide extensive information about
access patterns to healthcare services, useful information
for policy makers, while smaller and local studies should
find answers to specific problems and help the manage-
ment of local health services. However, this aspect is
directly connected to the research question and, conse-
quently, to the instrument that will be used or developed.
Instrument
The lack of consistency between instruments used to
evaluate medicine access and the large variability of
approaches poses difficulties to compare the studies and
confirms the subject as an area under major conceptual
and methodological building [20].
Most studies recruited individuals using as starting
point a visit to the doctor (during a certain period) and
investigated if the prescribed medicine was obtained.
Therefore, some instruments reveal more about health
services access than medicine access [8]. This kind of
instrument is adequate to evaluate medicines prescribed
for high-prevalent acute conditions, but impairs the eval-
uation of medicine access for chronic diseases, since
under this circumstance the visit to the doctor may have
happened long before the adopted recall period [9] and
does not detect the access to medicines that are not
dependant on prescription.
Thus, the choice for an instrument to study this topic
must consider the population type (general population,
service users, people living in the surrounds of primary
care units); the age group to be evaluated (all age groups,
only children, only adults, elderly people); and the kind of
medicine that will be evaluated (acute problems, chronic
problems, all kinds), only then the recall period and
recruitment methodology can be established. Those
aspects will influence the structure of the question(s)
about access; the chosen strategy to administer the ques-
tionnaire (face-to-face or self administered); and the
respondent definition (user, parents, caregiver, proxy or
family head). The quality of information will depend on
such characteristics and on the dropout rate of the study.
Population
The kind of sample to be studied (general population,
users or people living in areas covered by primary carePaniz et al. BMC Health Services Research 2010, 10:146
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units) will determine the kind of question about access to
be included in the study. When the general population is
interviewed, the study can describe how medicines are
obtained by all socioeconomic groups. When studying
public health services users and/or when the population
belongs to low socioeconomic groups, the main aspect to
be investigated is medicine free supply.
In a ddit ion  t o  t he  kind of  s a m pl e  t o  be  st udi ed,  a ge
groups must be considered as well. Many studies evalu-
ated all age groups and all included the elderly popula-
tion. Elderly people present high prevalence of chronic
conditions and constantly need to take more medicines
continuously, while children and adolescents mostly need
medicines to treat acute health problems.
Types of medicines
A great limitation found in the reviewed studies is the use
of the same methodology to investigate access to different
types of medicines (prescribed for chronic/acute diseases
and even not prescribed), hindering the quality of infor-
mation. The evaluation of medicine access to treat
chronic or acute conditions must rely on different recall
periods. Besides, during the planning of the study, the
goals of the research must be clear to define the inclusion
or not of over the counter medicines, adapting the ques-
tion for this definition. When asking if the individual
restrict medication during a certain period, over the
counter medicines will be included as well.
Recall Period
In studies about medicine access recall bias is a potential
source of error; respondents may recall better informa-
tion of the medicines they had access to. In an attempt to
control such problem, the recall period to be used in
medicine access studies depends on the medicine access
characterization, on the type of medicine to be evaluated
and on the studied age group.
As described previously, each medicine access defini-
tion considers different aspects. The access, defined as
obtaining prescription drugs, is employed to investigate
prescriptions from the last visit to the doctor during a
certain period (15-30 days), which is useful to measure
medicine access to acute health problems, and also to
evaluate chronic use of long-term medicines (12 months),
as long as restricted to the medicine type for specific con-
ditions. On the other hand, the underuse showed by one
of the studies [16], was based on a 12-month recall period
to evaluate cost-related lack of access to medicine pre-
scribed for chronic illnesses.
Usually, to measure medicine access for acute prob-
lems, a short recall period can be used and for chronic
conditions longer periods may be indicated to evaluate
problems affording prescriptions to continue treatment.
Therefore, in studies investigating medicine access for the
treatment of chronic and acute health problems, the
adoption of distinct recall periods must be considered.
Recruitment strategies to evaluate access
Often before measuring access it is necessary to define
inclusion criteria or use filter questions in order to allow
or restrict the type of medicine evaluated. Medicine
access studies are usually carried out within studies about
health services utilization because there is a need for a
diagnosis and consequent prescription. Because of that,
many times the recruitment of individuals for the study
takes place after the diagnosis of a specific illness and
treatment prescription or after a doctor visit that resulted
in a prescription. Another approach is to ask about medi-
cine use to treat specific diseases or to consult a list of
health service/facility users that attended the service dur-
ing a specific period. Consequently, the whole population
investigated by such studies may be much larger than the
sample considered during the evaluation of medicine
access.
Question to evaluate access
The questions to evaluate access focus mainly on two
aspects: medicine use/acquisition and underuse (due to
costs). According to the indicators suggested by WHO,
these evaluation strategies may actually measure the fol-
lowing access dimensions: availability, affordability or
both [1]. The questions that investigate if the individual
did not use/obtained the prescribed/needed medicine
allow two possibilities: if affirmative, the reason can be
investigated and, if negative, the information about
means of acquisition (paid or free) can be obtained - eval-
uating both dimensions. When lack of access due to cost
is investigated, other reasons are not assessed, restricting
evaluation to affordability.
Instrument administration, dropouts and prescription, 
packet or leaflet requesting
Most studies had large samples. On the other hand, the
two studies based on phone or internet interviews pre-
sented high refusal rates [16,17]. Despite such strategies
allow studying larger samples, the low response rate is a
major limitation. Besides, distant inquiry methods do not
allow asking for packets or prescriptions, impairing med-
icines identification. The packets or prescriptions
increase the accuracy and completeness of the informa-
tion obtained, minimizing memory bias. Medicine access
may be overestimated by the bias, since people recall bet-
ter medicine that they could obtain.
Name of the medicine
When the name of medicine is collected two different
analysis are possible: the first uses as denominator the
individuals and evaluates the amount of medicines
obtained compared to the needed number categorizingPaniz et al. BMC Health Services Research 2010, 10:146
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the result as total, partial or no access; the second uses
the number of medicines as denominator and measures
access to each pharmacologic group or chemical name of
the medicine. Even incomplete information can be used,
for example, if there is report of a medicine prescription
for a specific condition but the name of the medicine is
not available, the questions about medicine access can
still be answered or the reason for the lack of access, link-
ing these data to the condition that the medicine was pre-
scribed for.
On household surveys, to collect the name of the medi-
cine demands good training of the staff, considering that
interviewees usually are not able to inform it accurately.
When this is the case, to ask for the medicine packaging
or prescription and use help from other informers aware
of medicine regimen may increase the quality of data.
Respondents
When study subjects are children or elderly people, usu-
ally they are not aware of the details of medicine use and
access. For children, one of the parents needs to provide
the information while among the elderly usually a proxy
o r  a  p e r s o n  i n  c h a r g e  o f  c a r e  i s  i n t e r v i e w e d .  S o m e
reviewed studies do not allow identifying the respondent;
however this information is extremely important to eval-
uate the accuracy of information. Another group of stud-
ies excluded individuals unable to respond to the
questionnaire, and these individuals may need to take
regularly many medicines, presenting higher risk of
access barriers.
Conclusions
This review summarized methodologies employed to
evaluate medicine access on household level. In spite of
the increasing number of publications in the last five
years, due to the relevance of the theme, it is surprising
that such small number of studies was detected.
This paper revealed the variety of methodologies to
evalua t e medicine acc ess with r espect t o recall period,
sampling and characterization of the outcome - medicine
access.
Therefore, the standardization of medicine access indi-
cators such as acquisition, expenses and categorization
according to the dimension of evaluation (availability,
affordability, geographic accessibility, acceptability and
accommodation) is needed, as well as the establishment
of the appropriate recall period to assess each medicine
type and each access dimension, increasing comparability
across studies. Thus, as there is no standard methods to
evaluate household-level medicine access, as defined pre-
viously in this review, we propose studies targeted on
population access to all medicines, regardless of con-
sumption pattern (chronic or acute). Although both con-
sumption patterns are assessed together, specific
questions must be employed for on each situation. For
acute problems, a 15-day recall is appropriate, linking the
question to the acute health problem (including self-med-
ication) or to the medical appointment within this period
(specific to the medical indication) always asking for the
package and prescription, to obtain the medicine's name
accurately. With respect to chronic problems, a longer
recall period (from 30 days to twelve months) would be
appropriate to investigate underuse of the medicine and
the reasons for it. On those situations, the question must
be linked to the disease and package and prescription
should be used as well. However, on both approaches the
goals of the study, population and age groups to be stud-
ied must be established, to define the respondent of the
interview. Besides, specific keywords must be used to
allow future studies about medicine access.
Additional material
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
VMVP worked on the project, literature review and writing of the paper. AGF
worked on the project and writing of the paper. ADB worked on the project
and writing of the paper. MFSM worked on the literature review. MRD worked
on the writing of the paper and translation into English. All authors were
involved in the final review of the manuscript and all authors read and
approved the final manuscript.
Acknowledgements
The study is enrolled in Component 3 of the Project for the Expansion and 
Consolidation of the Family Health Program Strategy (PROESF), was supported 
by the Brazilian Ministry of Health and the World Bank, and received financial 
support from Brazilian Federal Agency for Support and Evaluation of Postgrad-
uate Education (CAPES) and from the Brazilian Council for Scientific and Tech-
nological Development (CNPq).
Author Details
1Programa de Pós-graduação em Epidemiologia, Universidade Federal de 
Pelotas, Pelotas, Brazil, 2Programa de Pós-graduação em Saúde Coletiva, 
Universidade do Vale do Rio dos Sinos, São Leopoldo, Brazil and 3Programa de 
Pós-Graduação em Educação Física, Universidade Federal de Pelotas, Pelotas, 
Brazil
References
1. Brasil, Ministério da Saúde, Organização Pan-Americana da Saúde, 
Organização Mundial da Saúde.  In Avaliação da assistência farmacêutica 
no Brasil: estrutura, processo e resultados Brasília: MS; 2005. 
2. PNUD (Programa das Nações Unidas para o Desenvolvimento): Objetivos 
de desenvolvimento do milênio.  .
3. WHO: WHO Medicines Strategy 2004-2007: countries at the core.  
Geneva WHO; 2004. 
Additional file 1 Table 1. Description of studies measuring medicines 
access on household level.
Additional file 2 Table 2. Population/medicines studied and definition of 
medicines access on household level.
Additional file 3 Table 3. Question/Logistics of instrument's administra-
tion in studies evaluating medicines access on household level.
Received: 26 July 2009 Accepted: 30 May 2010 
Published: 30 May 2010
This article is available from: http://www.biomedcentral.com/1472-6963/10/146 © 2010 Paniz et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. BMC Health Services Research 2010, 10:146Paniz et al. BMC Health Services Research 2010, 10:146
http://www.biomedcentral.com/1472-6963/10/146
Page 8 of 8
4. WHO: How to develop and implement a national drug policy.  Volume 6. 
Geneva WHO; 2003. 
5. WHO: Indicators for monitoring national drug policies: A Practical 
Manual.  2nd edition. Geneva WHO; 1999. 
6. WHO: Using indicators to measure country pharmaceutical situations. 
Fact Book on WHO Level I and Level II monitoring indicators.  Geneva 
WHO; 2006. 
7. WHO: WHO Operational package for assessing, monitoring and 
evaluating country pharmaceutical situations. Guide for coordinators 
and data collectors.  Geneva WHO; 2007. 
8. WHO (World Health Organization), MSH (Management Sciences For 
Health): Defining and Measuring Access to Essential Drugs, Vaccines, 
and Health Commodities. Report of the WHO-MSH Consultative 
Meeting.  Ferney-Voltaire France WHO MSH; 2000. 
9. Oliveira BB: Investigações de Acesso a Medicamentos em Nível 
Domiciliar: um estudo comparativo de iniciativas realizadas no Brasil 
entre 2002 e 2004.  In Dissertação Escola Nacional de Saúde Pública; 
2006. 
10. Leyva-Flores R, Erviti-Erice J, Kageyama-Escobar ML, Arredondo A: 
Prescripcion, acceso y gasto en medicamentos entre usuarios de 
servicios de salud en México.  Volume 40. Issue 1 Salud publica de 
Mexico; 1998:24-31. 
11. Bertoldi AD, de Barros AJ, Wagner A, Ross-Degnan D, Hallal PC: Medicine 
access and utilization in a population covered by primary health care 
in Brazil.  Health Policy 2009, 89(3):295-302.
12. Carvalho MF, Pascom AR, Souza-Junior PR, Damacena GN, Szwarcwald CL: 
Utilization of medicines by the Brazilian population, 2003.  Volume 21. 
Issue Suppl Cad Saúde Pública; 2005:100-108. 
13. Carvalho MFC: A polifarmácia em idosos no município de São Paulo - 
Estudo SABE - Saúde, Bem-estar e Envelhecimento.  In Dissertação 
Universidade de São Paulo; 2007. 
14. Fernandes MEP: A utilização de medicamentos na atenção à saúde, em 
nível domiciliar, no município de Fortaleza.  In Dissertação 
Departamento de Saúde Comiunitária, Universidade Federal do Ceará; 
1998. 
15. Paniz VM, Fassa AG, Facchini LA, Bertoldi AD, Piccini RX, Tomasi E, Thume E, 
Silva da Silveira D, Siqueira FV, Rodrigues MA: Access to continuous-use 
medication among adults and the elderly in South and Northeast 
Brazil.  Volume 24. Issue 2 Cad Saude Publica; 2008:267-280. 
16. Piette JD, Heisler M, Wagner TH: Cost-related medication underuse 
among chronically ill adults: the treatments people forgo, how often, 
and who is at risk.  Am J Public Health 2004, 94(10):1782-1787.
17. Reed M: An update on Americans' access to prescription drugs.  Issue 
Brief Cent Stud Health Syst Change 2005:1-4.
18. Tediosi F, Aye R, Ibodova S, Thompson R, Wyss K: Access to medicines 
and out of pocket payments for primary care: evidence from family 
medicine users in rural Tajikistan.  BMC health services research 2008, 
8:109.
19. Cesar CL, Tanaka OY: Inquérito domiciliar como instrumento de 
avaliação de serviços de saúde: um estudo de caso na região sudoeste 
da área metropolitana de São Paulo, 1989-1990.  Volume 12. Issue Suppl 
2 Cad Saúde Pública; 1996:59-70. 
20. Emmerick ICM: Avaliação da assistência farmacêutica no Brasil: um 
pensar sobre a abordagem de pesquisa proposta pela OMS e seus 
indicadores.  In Dissertação Escola Nacional de Saúde Pública; 2006. 
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-6963/10/146/prepub
doi: 10.1186/1472-6963-10-146
Cite this article as: Paniz et al., Measuring access to medicines: a review of 
quantitative methods used in household surveys BMC Health Services 
Research 2010, 10:146